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ContinuedSUMMARY
The Sc(III) MOF-type MFM-300(Sc) is demonstrated in this study to be stable un-
der physiological conditions (PBS), biocompatible (to human skin cells), and an
efficient drug carrier for the long-term controlled release (through human skin)
of antioxidant ferulate. MFM-300(Sc) also preserves the antioxidant pharmaco-
logical effects of ferulate while enhancing the bio-preservation of dermal skin fi-
broblasts, during the delivery process. These discoveries pave the way toward
the extended use of Sc(III)-based MOFs as drug delivery systems (DDSs).
INTRODUCTION
Metal-organic frameworks (MOFs) are one of the most recent classes of porous materials integrating a
unique chemical and topological richness with an almost infinite combination of metal ions and multiden-
tate organic linkers (Furukawa et al., 2013; Jiang et al., 2016; Kitagawa et al., 2004). This family of porous
solids first seen as a curiosity in the field of materials science, has been envisaged for further applications,
including but not limited to, gas storage (Makal et al., 2012; Murray et al., 2009; Suh et al., 2012), catalysis (Li
et al., 2012; Sumida et al., 2012; Wu et al., 2012), sensors (Chen et al., 2010a; Cui et al., 2012; Kreno et al.,
2012; Tchalala et al., 2019), electrical conductivity (Sheberla et al., 2014, 2017), and drug delivery (Chen and
Wu, 2018; Horcajada et al., 2012; Simon-Yarza et al., 2018). Some of these hybrid materials combine
outstanding adsorption/separation performances of highly challenging molecules with green synthesis
and easy scale-up that make them highly attractive to address a large panel of social concerns (Chen
and Wu, 2018; Horcajada et al., 2012; Simon-Yarza et al., 2018). In particular, MOFs show great potential
for the design of modern drug delivery technologies (Chen and Wu, 2018; Horcajada et al., 2012; Jie
and Ying-Wei, 2020; Simon-Yarza et al., 2018; Tibbetts and Kostakis, 2020). Unlike conventional drug car-
riers envisaged so far, e.g., micelles, liposomes, dendrimers, and mesoporous silica nanoparticles (Gillies
and Fre´chet, 2005; Porter et al., 2007; Senapati et al., 2018; Zhang and Ma, 2013; Zhang et al., 2012), MOFs
offer a unique opportunity to modulate the incorporated drug payload and release kinetics by a fine engi-
neering of their pore dimension (size/shape) and a fine-tuning of the nature/strength of the adsorption sites
decorating their internal pore walls as well as of the functionalization of their external surfaces (Liang et al.,
2019). The high degree of variability targets an efficient encapsulation of a broad range of highly chal-
lenging active pharmaceutical ingredients (APIs) in order to enhance their bioavailability and ‘‘shelf life’’
(Chen et al., 2018; Gime´nez-Marque´s et al., 2016; Horcajada et al., 2010; Liu et al., 2019; Luo et al., 2019;
Teplensky et al., 2017; Wang et al., 2018; Xiao-Gang et al., 2019; Ya-Pan et al., 2019; Ying et al., 2019). Cargo
drug loading in MOFs can be accomplished either by an encapsulation during the synthesis (Doonan et al.,
2017; Liang et al., 2015, 2019), or by a post-synthetic infiltration in the porosity of already-formed architec-
tures (Chen et al., 2018; Horcajada et al., 2010; Teplensky et al., 2017; Wang et al., 2018). This later strategy
has been widely explored in the development of controlled drug delivery systems (DDSs) of diverse natures
for a large number of therapeutic agents. However, when contemplating any nano-carrier materials for
biomedical applications several criteria are desired: (1) achieving an optimal drug loading efficiency (Hor-
cajada et al., 2012), (2) allowing the protection of the drug to avoid any degradation under physiological
media, (3) ensuring a gradual release of the drug once administrated to circumvent a ‘‘burst release effect’’
(Bellido et al., 2014; Li et al., 2017; Ruyra et al., 2015; Vela´squez-Herna´ndez et al., 2019), and (4) not having
toxic effects on the body. In this context, a number of porous MOFs, built up from bio-compatible metaliScience 23, 101156, June 26, 2020 Crown Copyright ª 2020
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Articleions, i.e., Ca(II), Mg(II), Zn(II), Zr(IV), Ti(III), and Fe(III), has been discovered (Chen and Wu, 2018; Chen et al.,
2018; Doonan et al., 2017; Horcajada et al., 2010, 2012; Liang et al., 2015, 2019; Simon-Yarza et al., 2018;
Teplensky et al., 2017; Wang et al., 2018). However, only a small fraction of them encompass the adequate
features to fulfill all requirements mentioned above (Chen and Wu, 2018; Horcajada et al., 2012;
Simon-Yarza et al., 2018). Typically, most of these MOFs suffer from a fast degradation in presence of phos-
phates, essential components in body fluids, hampering their applications for controlled drug delivery
(Bellido et al., 2014; Li et al., 2017; Ruyra et al., 2015; Vela´squez-Herna´ndez et al., 2019). The collapse of
the framework is induced by a highly favorable complexation of the phosphate species to most of the
metal centers tested so far, e.g., Zr(IV), Fe(III), and Zn(II) (Bellido et al., 2014; Li et al., 2017; Ruyra et al.,
2015; Vela´squez-Herna´ndez et al., 2019).
In this context, Sc(III)-MOFs have never been investigated for drug delivery applications to date. This is
likely mostly a result of the controversy on the bio-compatible nature of this metal. On the one hand, Sc(III)
was demonstrated to be reactive toward proteins owing to its ability to replace Ca(II) in many biochemical
events causing negative effects in enzyme systems and cell metabolism (Ford-Hutchinson and Perkins,
1971; Sa´nchez-Gonza´lez et al., 2013). On the other hand, Sc(III) is successfully used as a radioactive isotope
in medical applications (Horovitz, 2012; Szkliniarz et al., 2016), and a low concentration of Sc(III) was proven
to positively enhance specific antibiotic overproduction and have beneficial antibacterial effect (Kawai
et al., 2007). Therefore, this critically urges for a comprehensive study on Sc(III) MOFs for potential drug
delivery applications to address these open questions.
The present work reports the applicability of MFM-300(Sc), also denoted NOTT-400 (Ibarra et al., 2011), as
drug carrier for transdermal administration of ferulic acid (FA). FA is a natural superior antioxidant since its
phenolic nucleus and unsaturated side chain allow the formation of resonance-stabilized phenoxy radical
acting as free radical scavenger (Antolovich et al., 2004; Chen et al., 2010b; Zdunska et al., 2018). FA also
exhibits anti-diabetic, anti-cardiovascular, and anti-inflammatory properties (Antolovich et al., 2004; Chen
et al., 2010b; Zdunska et al., 2018). Interestingly, this molecule has a protective role for the main skin struc-
tures such as collagen, fibroblasts, keratinocytes, and elastin (Zih-yi et al., 2019). Consequently, this thera-
peutic agent has been widely used in skin care formulations as photoprotective agent and delayer of skin
photoaging processes and in the treatment of rosacea (Antolovich et al., 2004; Chen et al., 2010b; Zdunska
et al., 2018). Owing to the importance of FA as active ingredient in a variety of cosmetic products, trans-
dermal delivery is themost common administration route (Zih-yi et al., 2019). However, on premature expo-
sure to sunlight FA undergoes oxidation reactions leading to the formation of quinones, dimers, and alde-
hydes (Antolovich et al., 2004). The photodegradation of FA not only limits its shelf-life but also reduces its
effectiveness before it permeates the stratum corneum (SC) (Antolovich et al., 2004), which is the most su-
perficial layer of the epidermis, and acts as skin barrier (Kalpana et al., 2010; Pegoraro et al., 2012). In order
to circumvent these limitations, herein, we propose to encapsulate FA in the pores of MFM-300(Sc) with the
main idea to prevent the photodegradation process of FA and to allow its continuous and sustained release
over time that does not require frequent dosing.Building, University Avenue,
Glasgow G12 8QQ, UK
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MFM-300(Sc) as Drug Carrier of FA (FER–)
MFM-300(Sc) of chemical formula [Sc2(BPTC) (OH)2], was synthesized and activated according to a previ-
ously reported procedure (Supplemental Information) (Ibarra et al., 2011). A series of characterization tools
confirmed the phase purity of the material and the full activation of its porosity (see Supplemental Informa-
tion). This MOF crystallizes in the chiral tetragonal space group I4122, with each [Sc2(m-OH)] (Figure S1) bi-
nuclear center octahedrally coordinated to six O-donors, four from four different carboxylate groups of
BPTC4 ligand (BPTC4, biphenyl-3,30,5,5-tetracarboxylate) and two from two different m-OH groups, lead-
ing to a 3D framework with a channel of about 8.1 A˚ (Figure S1) (Ibarra et al., 2011). To evaluate the capacity
of MFM-300(Sc) as drug delivery carrier, ferulic acid was initially loaded as ferulate species (FER–) (vide infra)
within the MOF by a simple impregnation process, i.e., aqueous solution of ferulic acid (FA) at pH = 9
(Supplemental Information). Since the pore opening of MFM-300(Sc) exceeds the dimension of the drug
(10.0 3 7.1 3 1.8 A˚3), FER– is expected to be confined in its channels. UV-vis absorption spectroscopy
was employed to monitor the concentration of FER– during the impregnation process (Figure S2).
The maximum FER– payload (16.1 wt%) was achieved after 5 days of incubation; we determined this per-
centage by quantifying free FER– in the supernatants when the MOF dispersion was centrifuged (Supple-
mental Information). The drug content was further corroborated by TGA analysis (Figure S5). Powder X-ray2 iScience 23, 101156, June 26, 2020
Figure 1. Controlled Release of FER in FER@MFM-300(Sc)
Comparison between the in vitro release profile of free FER– (red circles) and the FER– delivered from the MFM-300(Sc)
thorough the dialysis bag technique (blue circles). Five independent in vitro experiments were performed to generate
the error bars (statistics). Lines are shown to guide the eyes. A schematic representation of the release of FER– from a
FER@MFM-300(Sc) composite is shown as inset. See also Figures S1, S3, and S6.
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shows that the impregnation process does not modify the crystalline structure of MFM-300(Sc) (Figure S3),
whereas N2 adsorption measurements revealed a decrease of the Brunauer, Emmett and Teller (BET) area
and pore volume with respect to the pristine solid (915 m2 g1 and 0.39 cm3 g1 versus 1,300 m2 g1 and
0.56 cm3 g1, respectively) (Figure S4). Grand Canonical Monte Carlo (GCMC) simulations (see Supple-
mental Information for details) further predicted a lower uptake of FER– confined in the pores (10.7 wt%)
associated with a decrease of the theoretical N2-accessible surface area from the empty to the
FER@MFM-300(Sc) materials (1,480 m2 g1 versus 1,290 m2 g1). This strongly suggests that part of the
experimental payload is not associated with a confinement of FER– in the pores of the MOF.
The drug-release kinetics of FER@MFM-300(Sc) was further assessed by in vitro studies using a dialysis bag
diffusion technique (Supplemental Information). Two distinct regimes can be distinguished in the drug-
release profile (Figure 1). Initially, ca. 37.0% of FER– is released within the first 6 h; this fast initial release
is associated with the well-known burst effect (Bellido et al., 2014; Li et al., 2017; Ruyra et al., 2015; Vela´s-
quez-Herna´ndez et al., 2019), and we can exclude that it is related to the degradation of MFM-300(Sc), since
we have evidenced that the structure maintains its integrity after the drug release experiments and under
the simulated physiological conditions used for the cytotoxicity assays (Supplemental Information, Fig-
ure S3). Interestingly, this payload (6.4 wt%) corresponds roughly to the deviation between the total exper-
imental uptake and the predicted value for FER– confined in the pores (5.4 wt%). This first regime is thus
most probably assigned to the release of FER– initially adsorbed at the external surface of theMOF. In other
words, this first FER– release does not come from the micropores of MFM-300(Sc). This most likely comes
from the external surface of the MOF crystals. Conversely, in the second regime the release process is
considerably slower, releasing ca. 53% of the loaded drug during further ca. 94 h, approximately 4 days.
Release of 9.7 wt% (end of the experiment) is in good agreement with the 10.7 wt% predicted by our cal-
culations, supporting that this corresponds to the delivery of FER– initially confined in the pores of the MOF
material.iScience 23, 101156, June 26, 2020 3
Figure 2. Microscopic Illustration of FER– Adsorption in the MFM-300(Sc) Porosity
Representative MC snapshots of the FER– adsorption in MFM-300(Sc) (A) at the dry state, displaying the single-adduct
between the FER– carboxylic groups and the m-OH groups of the pore wall and (B) in solution, showing the FER–
interactions with H2O molecules forming either (1) a single adduct with the m-OH groups of the pore wall or (2) clusters at
the center of the pore. Sc, O, C, and H are, respectively, represented in yellow, red, gray, and white. MFM-300(Sc) atoms
are shown translucid for clarity. H-bonds are shown in dashed blue lines. Captions associated to the RDFs are described in
the text.
See also Figures S2, S7, S13, S14, and S15.
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Monte Carlo (MC) and Density Functional Theory (DFT) calculations were further combined to understand
the microscopic origin of this slow release. Analysis of the MC configurations for the adsorption of FER– in
the dry state revealed that the drug molecule establishes relatively strong hydrogen bonds with the m-OH
functional groups of MFM-300(Sc) via their carboxylic groups with characteristic OCOO- - Om-OH distance of
ca. 3.0 A˚ as seen by the corresponding radial distribution functions (RDFs) plotted in Figure S15A. Such an
arrangement illustrated in Figure 2A leads to a high DFT-calculated binding energy (43.5 kcal∙mol1) that
needs to be overcome in order for the molecules to be expelled from the MOF framework. Our MC simu-
lations performed in solution further evidenced that FER– species interact strongly with water via their car-
boxylic groups with characteristic short OCOO- - OW distance of 2.5 A˚ as seen by the corresponding RDF
plotted in Figure S15B. A fraction of these water molecules equally establishes strong hydrogen bonds
with the m-OH groups of the MOF pore wall with characteristic Ow - Om-OH distance of 2.7 A˚ (Figure S15B).
This concerted FER– water and water-MOF interaction scenario offers an optimal scenario to stabilize FER–
species in the confined environment, water playing a pivotal role by acting as a bridge between the MOF
pore-wall and FER– to retain strongly the drug as can be seen in Figure 2B. One can also notice that besides4 iScience 23, 101156, June 26, 2020
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Articleforming a strong hydrogen bond network, as seen by the high intensity of the peak at 2.8 A˚ in the RDF cor-
responding to the Ow – Ow pairs (Figure S15B), the water molecules form side interactions with the other
functional groups of FER– (Figures 2B and S15B). DFT simulations further confirmed that such an arrange-
ment of FER– is highly stabilized with a corresponding binding energy of120 kcal∙mol1, consistent with a
slow release observed experimentally. In line with these computational simulations, the experimental 13C
CP MAS spectra (Figure S7) confirm the interaction of FER– within the MOF material. In the spectrum of
FER@MFM-300(Sc), the NMR signals originating from FER– are considerably lower in comparison with
those for MFM-300(Sc). Two signals are observed in the carboxylate region; the first one at 174.9 ppm is
the most intense and is attributable to COO– bonded to Sc+3 in MFM-300(Sc). The second one appears
at 170.7 ppm and is attributable to COO– coming from the FER– species. The signal of COO– FER–$$$Na+
appears at 173.1 ppm, i.e., that COO– shifted 2.4 ppm to stronger fields when adsorbed in MFM-300(Sc)
(Figure S7).
Indeed, the drug adsorption profile accomplishes the desired drug-delivery kinetic for transdermal drug
administration applications, where the drug carrier systems are designed normally to release the cargo
within 1–7 days.
Cytotoxicity Experiments
Accordingly, the cytotoxicity of MFM-300(Sc) and its components (BPTC4, Sc+3) were investigated sepa-
rately, monitoring their impact in the cell viability and proliferation of human dermal fibroblasts (Supple-
mental Information) (Kalpana et al., 2010). Five different concentration solutions (5, 25, 100, 250, and 500
ppm) of BPTC4, Sc+3, and MFM-300(Sc) were tested (Supplemental Information). The collected data re-
vealed that bothMFM-300(Sc) and Sc+3 did not considerably affect the cell viability, in comparison with pos-
itive controls. More than 98% of the cells remain viable after 24 h of incubation at any of the concentrations
employed (Figures 3 and S9). This behavior remained almost constant even after 120 h. However, the culture
well plates pre-treated with BPTC4 presented a considerable reduction of cell viability in a dose-depen-
dent way. Since some cells separate from the culture plate when they are not viable, the number of cells
was also assessed. The cells treated with MFM-300(Sc) only showed an 80% reduction of the number of
live cells at 500 ppm. Cells treated with Sc+3 showed a 120% reduction at 25–500 ppm. Treatments with
BPTC4 decrease considerably the number of cells from 5.5 times at 5 ppm to 8.8 times at 500 ppm. More-
over, the cell images collected on an epifluorescencemicroscope showed that, even when using only 5 ppm
of BPTC4, in the incubation media, the cells adopt a rounded morphology. This last observation indicates
that the fibroblast attachment was not appropriate on the culture wells pre-treated with BPTC4 (Figures 3
and S9). These results not only demonstrate that Sc+3 and MFM-300(Sc) exhibit an acceptable biocompat-
ibility for topical drug administration but also confirm that BPTC4 shows a negative cytotoxic effect.
These findings encouraged us to investigate the transdermal permeability of FER– upon the topical admin-
istration of this antioxidant using FER@MFM-300(Sc) as a drug carrier. An active ingredient will exert its ef-
fect on its therapeutic target by releasing it from its pharmaceutical form, and it will subsequently arrive at
its site of action.
Evaluation of the Antioxidant Effect of FER– Released from the MFM-300(Sc) Matrix
The ex vivo permeation assays were carried out on Franz diffusion cells using low back human tissue (Figures 4A
and S10). This tissue was obtained from a female donor, who underwent aesthetic surgery, and it was employed
with the prior consent of the donor (Supplemental Information, Figure S10). The Franz chambers consist of two
compartments (donor and receptor) separated by the skin membrane (Figure 4A). The skin was placed in the
donor compartment, where the stratum corneum (SC) was exposed to a suspension of FER@MFM-300(Sc)
(41.4mgmL1) (Figures 4B and S10). The receptor compartment was filledwith PBS (phosphate-buffered saline)
at 37Candkeptunder stirring (500 rpm) for 87h.Afterward, the receptormediumwas sampled todetermine the
amount of antioxidant diffused across the skin barrier (referred as systemic diffusion). As a control test, this
permeation experiment was also performed using an aqueous suspension of FA (6.68 mg mL1) (Figure 4C).
Then, once completed the permeation assay, the skin samples were further analyzed to determine the bio-
distribution of the antioxidant within the skin layers. The tape stripping technique was employed to remove
theSC layerofeach skin sample (Binderetal., 2019;Escobar-Cha´vezetal., 2008;Espositoetal., 2018; Limcharoen
et al., 2019). Then, these tape stripping samples and the remaining part of each skin sample were analyzed to
estimate the amount of the antioxidant retained in the SC and in the inner layers of the skin. The data collected
show that, when using the FER@MFM-300(Sc) system, ca. 10.40%of the cargo permeates through the skin to theiScience 23, 101156, June 26, 2020 5
Figure 3. Cytotoxicity Experiments of MFM-300(Sc), Sc+3, and BPTC4
(A) Viable (green/calcein positives) and dead (red/EthD-1 positives) cells seeded on culture well plates pre-treated with different concentrations of MFM-
300(Sc), Sc(III) and BPTC4.
(B) Viable cell percentage and (C) total number of viable cells. ANOVA test and Sidak’s multiple comparisons test. *p < 0.05, **p < 0.005, ***p < 0.0005 and
****p < 0.00005. Scale bars correspond to 100 mm.
See also Figures S9 and S12.
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reaches the receptor compartment (Figures 4B and 4C), presumably because of oxidation and poor solubility of
free FA in the skin. Interestingly, the amount of the antioxidant retained in the SC when using the FER@MFM-
300(Sc) formulation and free FA is comparable ca. 0.20% and almost negligible, respectively. The carrier
(MFM-300(Sc))was retained in theSCasdemonstratedby the sizeof thecrystals (FigureS8). Inaddition, thequan-
tity of the drug retained in the dermal and epidermal layers is around 0.29%when using FER@MFM-300(Sc) and
0.39%in thecaseof freeFA.ThepermeationfluxesdeterminedforFER–andFER@MFM-300(Sc)were12.13104
and 5.9 3 104 (nmol$cm2$h1), respectively. These findings demonstrate that our carrier material (MFM-
300(Sc)) improves the permeation of the drug through the human skin, in comparison with the free FA. Such dif-
ferences might be attributed to the promotion in the absorption of FER– inside FER@MFM-300(Sc) possibly by
transcellular or paracellular routes. In addition, there is a higher availability of thedrugwhen it is administratedas
the ion FER– species than when it is administrated directly as the protonated species (FA).
Thus, the poor solubility of FA in the aqueous suspension, as well as its propensity to oxidize, reduces the
concentration of the availablemolecular species retarding the permeation through the skin layers. The ther-
apeutic reach of the permeation of FER– from FER@MFM-300(Sc) in the epidermis-dermis region, systemic,
or deposition from the SC, also implies the subsequent prolonged release for up to 5 days of the cargo with
the innocuous biodegradation of the carrier, a requirement of special interest for chronic clinical conditions.
Evidence of non-permeation of FER@MFM-300(Sc) was recorded by SEM studies before and after the tape
stripping technique owing to the particle size of FER@MFM-300(Sc) (5 3 13 mm), which corroborates the
new system as only for modified release and not for permeation (Figure S11). It is worth to emphasize6 iScience 23, 101156, June 26, 2020
Figure 4. Ex Vivo Permeation Experiments of Free and Entrapped FER–
(A–C) (A) Structural design of a Franz diffusion cell and schematic representation of the skin layers; (B) ex vivo permeation
experiments of FER– using the FER@MFM-300(Sc) formulation, and amount of antioxidant (%) retained within the skin and
released in the receptor chamber (systemic); and (C) ex vivo permeation experiments using an aqueous suspension of free
FA and percentage of antioxidant retained within the skin and released in the receptor chamber (systemic).
See also Figures S8, S10, and S11.
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certain level of statistics because of the limitations of achieving reproducible samples (same origin of
the human skin: ideally same patient, same area of extraction, age of the donor, sex, ethnicity, etc.).
More than focusing on the absolute permeation values of FER–, it is very significant the trends that we show.
Finally, to examine if the therapeutic drug preserved its antioxidant pharmacological effects after the long-
term release process, the antioxidant efficacy, of FER– released from the microporous carrier (MFM-
300(Sc)), was tested by monitoring the reactive oxygen species (ROS) produced in dermal skin fibroblasts
upon being treated with H2O2. First, the release of the antioxidant was performed by soaking the MOFiScience 23, 101156, June 26, 2020 7
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Articlecomposite (FER@MFM-300(Sc)) in the cell culture media for 5 days. Then, the fibroblasts were pre-treated
with this incubation media for 20 min. Subsequently, the cells were exposed to H2O2 for 20 min to induce
the oxidative stress. The efficacy of the antioxidant in protecting skin fibroblasts from H2O2-induced ROS
toxicity was determined using CellRox flow cytometry assay (see Supplemental Information, Figure S9). The
results obtained demonstrated that the unstained condition marks 100% of cells without ROS expression
(CellRox+), dead cells (7-AAD+), or doubly marked (CellRox/7-AAD+). In the basal state (without H2O2
treatment), only 0.2% of the cells remain unlabeled and 67.5% show ROS expression, whereas, as expected,
the cells incubated with H2O2 present an increase in ROS production (88.7%), the unlabeled population de-
creases (0.6%), and the population with dead cells and ROS + showed 10.7%. However, when the cells were
treated with FER@MFM-300(Sc) (100 ppm) the percentage of unstained cells (without ROS or dead cell
staining) increase considerably (25.9%) in comparison with the values observed in the basal state (0.6%).
This fact confirms that the FER– released from FER@MFM-300(Sc) maintains its bio-functionality by
scavenging ROS species. Another result shows that only the application of the MFM-300(Sc) to the cells in-
crease the unlabeled cells from 0.6% to 1.3%, suggesting that the MFM-300(Sc) exhibits an unexpected
antioxidant capacity. These findings suggest that FER@MFM-300(Sc) not only allows the long-term
sustained release of FER– but also enhances the bio-preservation of dermal skin fibroblasts during the
delivery process.
In summary, this work demonstrates that MFM-300(Sc) is an efficient drug carrier by virtue of its excellent
biocompatibility in human skin cells, remarkable stability under physiological conditions, and adequate
controlled release for topical applications. The incorporation of FER– into MFM-300(Sc), in comparison
with other well-known or even commercial materials like hydrotalcites (Lima et al., 2013), provided a
longer-term controlled release through human skin. MFM-300(Sc) also demonstrated a higher chemical
stability in comparison with typical MOF DDSs like MIL-100 and MIL-101(Horcajada et al., 2006; Li et al.,
2017). This particular chemical stability for MFM-300(Sc) provides a benchmark material for future investi-
gations in order to compare with other MOF carries, particularly those constructed with Sc(III) metal
centers. In addition, our study reveals that this material improves the systemic delivery of ferulate leading
to the controlled and sustained long-term delivery of the cargo, which avoids both the degradation of
ferulate, and the continuous re-application of the drug during, relatively, a long time. These findings
pave the way toward the extended use of Sc(III)-based MOFs as drug carriers.Limitations of the Study
In this study, the topical drug bioavailability was assessed by in vitro experiments using a two-chamber
Franz cell. The main disadvantage of this system is that it does not consider the in vivo skin processes
and does not mimic accurately the living state of the skin. For instance, the skin normally functions
under air from the environment. However, during the permeation studies, SC is typically exposed to wet
conditions for prolonged periods. On the other hand, the current work was limited to the release of
FER–. Future efforts should test other drugs in order to drive the extended use of Sc(III)-based MOFs as
drug carriers.Resource Availability
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Supplemental Figures 
 
 
 
 
 
 
Figure S1. (left) space-filling view of the structure of MFM-300(Sc) along the b-axis showing 8.1 Å channels 
(Reproduced from(Ibarra et al., 2011)  with permission from The Royal Society of Chemistry); and (right) view of 
the coordination at Sc(III) in MFM-300(Sc), showing [BPTC]4− and the μ2-OH group (Reproduced from(Ibarra et 
al., 2016) with permission from The American Chemical Society). 
Figure S2. Drug loading quantification: (left) Absorbance scan of FER– in 1.0 M PBS, pH=7.4 by UV-vis 
spectrophotometry with detection at 206 nm. Concentration range from 5.3 to 87.5 µg/mL; and (right) 
corresponding FER– equation Absorbance=0.018[FER–]-0.046 with a correlation coefficient of 0.999. 
 
 
 
 
Figure S3. PXRD patterns for simulated MFM-300(Sc) (black), as-synthesised MFM-300(Sc) (red), MFM-300(Sc) 
after inmersion in PBS (1.0 M) for 5 dyas and pH=7.4 (blue), FER@MFM-300(Sc) (purple) and MFM-300(Sc) after 
drug-release experiment (green), demonstrating the structural integrety upon PBS contact for (time), upon FER- 
loading and release. 
Figure S4. N2 isotherm of MFM-300(Sc) (black) (BET area and pore volume of 1300 m2 g–1 and 0.56 cm3 g–1, 
respectively) and FER@ MFM-300(Sc) (red) (BET area and pore volume of 915 m2 g–1 and 0.39 cm3 g–1, 
respectively). Showing a decrease in posority of MFM-300(Sc) indicantes FER– loading within the pores of the 
MOF material.  
  
 
 
Figure S5. TGA of the as-synthesised FER@MFM-300(Sc) with a rate of 2°C/min (orange), 5°C/min (blue) 
and the salt of FER– (black). 
 
Figure S6. FTIR spectra of salt-FER has a series of peaks, such as 3435 cm−1 (–OH stretching), 1689 and 
1663 cm−1 (stretching vibration of C=O groups), and 1514 cm−1 (C=C aromatic ring). Compared to MFM-
300(Sc), the intensity around the aforementioned peaks in the FER@MFM-300 (Sc) increased, indicating 
that ferulic acid was grafted into the MOF. 
 
  
Figure S7. 13C CP MAS NMR spectra of a) the FER–···Na+ salt; b) MFM-300(Sc) and c) 
FER@MFM-300(Sc). Signals labeled * are spinning side bands. 
Figure S8. Scanning electron microscope images of: (a) metal-organic frameworks MFM-300(Sc) and 
FER@MFM-300(Sc) with 16.15 wt% of FER– loading; (b) the crystal dimensions of MFM-300(Sc), 
magnified 5,000x. 
   
Figure S9. a) Shows viable (green/calcein positives) and dead (red/EthD-1 positives) cells seeded on culture 
well plates pre-treated with different concentrations of MFM-300(Sc), Sc(III) and BPTC-4 (20x from Figure 3). b) 
show the cell percentage and c) the total number of viable cells. ANOVA test and Sidak´s multiple comparisons 
test. *p<0.05, **p<0.005, ***p<0.0005 and ****p<0.00005. Scale bars correspond to 100 μm. 
 
 
Figure S10. Franz cell images of: (a) tissue extended and pretreated for using, (b) tissue placed in customised 
Franz cells for diffusion studies with suspensions of FER@MFM-300(Sc) and FA; and (c) tissue after of diffusion 
process. 
  
Figure S11. Scanning electron microscope images of the stratum corneum (SC) of untreated 
skin and treated with free and adsorbed FER– in the FER@MFM-300(Sc) system, before 
and after the tape removal technique. 
 
 
 
Figure S12. Flow cytometric dot plots of skin dermal fibroblasts with and without a pretreatment 
with a culture medium supplemented with FER@MFM-300(Sc) prior to exposure to H2O2. The 
graphs show the following populations: dead (Q1; 7-AAD), double stained (Q2; CellRox/7-AAD), 
not stained (Q3) and ROS positives (Q4; CellRox). All of the populations were analysed with the 
different experimental conditions. 
 
 
 
 
 
 
 
 
 
 
Figure S13. Illustration of the DFT-optimised MFM-300(Sc) structure (left), description of the different atom types 
(upper right) and their corresponding charges (lower right).  Sc, C, O and H atoms are respectively represented in 
yellow, grey, red and white. 
Figure S14. Illustration of the Na+ and FER– ions showing its atom types (left) and their corresponding atom charges 
(right). Na, C, O and H atoms are respectively represented in ochre, grey, red and white. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S15. Radial distribution functions (RDFs) obtained from MC calculations at 310 K.  (a) in the dry state, 
interactions between the O atoms of the COO– functions of FER– and the O atoms of the µ-OH groups of the 
MOF. (b), at the hydrated state, interactions between the oxygen atoms of the water molecules themselves 
(black line) and with the oxygen atoms of the µ-OH groups (red line) of MFM-300(Sc) and with the oxygen atoms 
of the carboxylic (blue line), ether (orange line) and phenol (green line) functional groups of FER–. 
 
 
 
Transparent Methods 
 
1. Experimental  
 
Synthesis of MFM-300(Sc)  
MFM-300(Sc) ([Sc2(OH)2(BPTC)]) was synthesized according to a procedure previously reported:(Ibarra et 
al., 2011) Scandium triflate (0.030g, 0.061 mmol) and H4BPTC (0.010 g, 0.030 mmol) were mixed in THF 
(4.0 mL), DMF (3.0 mL), water (1.0 mL) and HCl (36.5 %, 2 drops). The resultant slurry mixture was stirred 
until complete dissolution occurred. The solution was then placed in a pressure tube and heated in an oil 
bath to 75 oC for 72 h. The tube was cooled down to room temperature at a rate of 0.1 oC/min, and the 
colourless crystalline product was separated by filtration, washed two times with DMF (5.00 mL) and dried 
in air. Yield: 65.3 % (based on ligand). 
Activation of MFM-300(Sc)  
Acetone-exchanged (three times) samples of MFM-300(Sc) were activated at 180 oC and 1.7×10-3 Torr for 
12 h. 
Synthesis of FER@MFM-300(Sc)  
FER@MFM-300(Sc) was prepared by following an impregnation protocol: 60 mg of desolvated MFM-
300(Sc) (previously acetone-exchanged and activated at 180 oC and 1.7×10-3 Torr for 12 h. Then this 
activated sample was dried for 48 hours at 65° in an oven) were soaked into an aqueous solution of ferulic 
acid (FA) (20 mL, 0.5 mg mL–1) at pH = 9 (at this pH, FA is present as an anion (analogue) ferulate (FER–). 
This mixture was stirred (600 RPM) at room temperature for 5 days. Afterwards, the sample was 
centrifuged at 12,500 RPM for 30 minutes. The concentration of FER– in the supernatant was analysed by 
UV-vis spectroscopy: The FER– content in FER@MFM-300(Sc) was calculated by quantifying FER– in the 
supernatant after centrifuging at 12,500 rpm for 30 min. The maximum absorbance peak was determined 
in a scan of 180 to 400 nm at a speed of 10 nm/s, as depicted in Figure S2 (left). The absorbance data 
were recorded at 206 nm and interpolated in a calibration curve in the concentration range of 5.3 to 87.5 
µg/mL described by equation Absorbance=0.018[FER–]-0.046 with a correlation coefficient of 0.999 (see 
Figure S2, right). The drug loading was estimated as 16.15 wt%, corresponding to 0.31 mol of FER– per 
mol of FER@MFM-300(Sc). The result was corroborated by thermogravimetric analysis (TGA), vide infra 
(Figure S5).  
The material collected was washed once with distilled water, and recovered by centrifugation. Finally, the 
material was resuspended in 3 mL of distilled water and lyophilised. The lyophilization process lasted 12 
h and was carried out at -49 °C, with a vacuum of 0.021 Torr. 
Additionally, to confirm the amount of drug loading within FERMFM-300(Sc), FER– was quantified by using 
a dialysis membrane method (vide supra). The total amount of quantified FER– was equal to 15.88 wt%, 
in good agreement with the initial drug loading.  
Powder X-ray diffraction (PXRD)  
The diffraction patterns were collected in Rigaku ULTIMA IV powder diffractometer equipped with a Lynx-
eye detector using Cu Kα1,α2 radiation (λ = 1.54051, 1.54433 Å) from 2° to 30° (2θ) and a step size of 
0.05° and 4 s per step in continuous mode.  
N2 adsorption isotherms 
N2 isotherms were performed on a Belsorp mini II analyzer under vacuum (10−3 bar). Samples of MFM-
300(Sc) and FER@MFM-300(Sc) were activated at 100 °C for twelve hours and at 180 °C for two hours, 
respectively (under vacuum, 10−3 bar). 
Thermogravimetric analysis (TGA)  
Samples were analysed under nitrogen flow (20 mL min−1) using a TGA Q5000 running from room 
temperature to 600 °C with a heating rate of 2 °C min−1 and 5 °C min−1. 
FTIR Spectroscopy  
FTIR spectra were measured (at room temperature) using an FTIR Nicolet 6700 spectrophotometer. 
NMR analysis  
CP-MAS 13C NMR spectra of the samples were recorded with a Bruker AVANCE III HD 300 MHz 
spectrometer FX-200 under the following conditions: 90° pulse, pulse width; 4 µs, pulse repetition; 5 s, 
pulse interval (cross polarization contact time); 7kHz spinning rate. The Chemical shift values in spectra 
were referenced to TMS. 
Scanning electron microscopy images (SEM)  
SEM were recorded using a JEOL Benchtop Scanning Electron Microscope, Neoscope JCM- 6000 using 
secondary electrons at 15 kV current in high vacuum. 
 
2. in-vitro and ex-vivo studies of FER@MFM-300(Sc) 
 
Evaluation of the in-vitro release of the antioxidant 
The release profile of the antioxidant was obtained using a dialysis membrane method. FER@MFM-
300(Sc) (30 mg) was resuspended in 1 mL of phosphate buffer saline media (PBS) (1.0 M, pH 7.4). This 
mixture was poured into a dialysis bag and placed into a beaker containing 100 mL of PBS (1.0 M, pH 
7.4). The incubation medium was maintained under stirring (600 rpm) at 37 °C for 8 days. At pre-
established times (0.5, 1, 2, 4, 6, 24, 72, and 192 h), aliquots (3 mL) were extracted, and replaced with 
fresh medium to maintain the “sink” conditions. The kinetics of the drug release were followed through 
the quantification of the drug by UV-vis spectroscopy (UV-2600, Shimadzu, put this info in general 
information) at a wavelength of 216 nm, previous validation of the analytical method. 
After the drug-release profile experiment, we recover the solid and PXRD experiment demonstrated the 
retention of the crystallinity of the MOF material (Figure S3). This result corroborates that the phosphate 
buffer saline media (PBS) (1.0 M, pH 7.4), did not break the framework structure of MFM-300(Sc). 
Cytotoxicity assays  
To test whether the components of MFM-300(Sc) and the material itself might affect cell viability, human 
dermal fibroblasts at passage 2 were used. Cells were grown in DMEM/F12 medium (Gibco) 
supplemented with Fetal Bovine Serum (FBS) at 10% v/v (Gibco) and penicillin/streptomycin (Gibco) at 
1% v/v. Five different concentration solutions (5, 25, 100, 250 and 500 ppm) of the components (Sc+3 and 
BPTC-4) and MFM-300(Sc) were tested in two different cellular assays. For the first assay, solutions were 
prepared in double distilled water; then, 48-well culture plates were pre-treated by independently adding 
100 µL of each component solutions and allowing them to dry for 2 h under sterile conditions; DMSO 
pre-treated culture wells were used as positive controls. Immediately after solution drying, fibroblasts 
were seeded (1.0 x103 cells/cm2) in the pre-treated well culture plates and incubated with supplemented 
DMEM-F12 for 24 h at 37 ºC and 5% of CO2. Finally, cell viability was analysed using the LIVE/DEAD® 
Calcein/Etidium homidimer kit assay (Thermo) (Figure S9). For the second cellular assay, cells were seeded 
directly on non-treated 48-well culture plates and incubated in supplemented DMEM-F12 at 37 ºC and 
5% CO2 for 24 h to allow proper cell adhesion. Then, culture medium was replaced, independently, with 
the different materials solutions (5, 25, 100, 250 or 500 ppm) prepared in supplemented DMEM-F12. 
Afterwards, the cells were further cultured for 24 h at 37 ºC and 5% of CO2. For positive controls, fresh 
DMEM-12, instead of materials solutions, was added to culture wells plates. Finally, cell viability was 
studied using the LIVE/DEAD® Calcein/Etidium homidimer kit assay (Thermo). For both cellular tests 
Calcein-AM/Etidium homidimer assay was performed according to kit manufacturer guidelines. Briefly, 
cells were incubated with 1 μM calcein and 2 μM Ethidium homodimer for 30 minutes; then, cells were 
washed with PBS 1X (Gibco) and maintained in supplemented DEM-F12. Photographs were immediately 
acquired using an epifluorescence microscope (Zeiss) and percentage of viable cells over total number of 
cells was calculated from the micrographs using the Image J software.  
ex-vivo permeation assay in human skin by Franz cells 
Franz's cell permeation model was used to determine the permeation capacity of the FER@MFM-300(Sc), 
simulating a topical application of the drug. Human tissue was employed, prior approval of the letter of 
consent and following the guidelines of the protocol approved by the National Rehabilitation Institute 
(Mexico City, Mexico) #5454 and the declaration of Helsinki. The tissue was conditioned in a medium of 
saline solution with antibiotics and conserved in an airtight bottle at 5 °C between first 12 hours after 
being extracted; the thickness of the skin was 7mm. For the donor compartment, the formulations 
FER@MFM-300(Sc) and aqueous dispersion of FA, equivalent to 4.15 x 10-4 mol of FER– were resuspended 
in 1 mL of deionized water. A control negative was established as tissue without formulation. The receptor 
compartment consisted of a phosphate buffer pH 7.4 that simulated a physiological medium. The 
experiments were conducted in a thermal bath to preserve the temperature of 37 °C, and a stirring speed 
of 500 rpm for 87 h. Afterwards, an aliquot of 3 mL was extracted from the receptor chamber and was 
analyzed by UV-Visible at 216 nm to determine the amount of the cargo that diffuses through the skin 
layers. The tests were carried out by triplicate. Finally, the skin samples were carefully removed from the 
Franz cells to conduct the tape-stripping procedure with 5 successive tape strips (Scotch® 3M®), following 
in-vivo permeation assay methodology (vide infra). All tapes were introduced into a flask with 15 mL of 
acetone, and this was mechanically stirred for 24 h. Subsequently, each skin sample was fragmented into 
small pieces using surgical scissors, and the drug was extracted with 15 mL of acetone (24 h). All samples 
were analyzed by UV-vis spectrophotometry at a wavelength of 327.5 nm. 
 
Evaluation of the antioxidant effect of FER– released from the MFM-300(Sc) matrix.  
The antioxidant effect of ferulate (FER–) released rom MFM-300(Sc) was evaluated using dermal skin 
fibroblasts donated from aesthetic surgeries (after signing the letter of informed consent), and treated 
according to the preestablished protocol.(Pérez-Díaz et al., 2015) The FER@MFM-300(Sc) was incubated 
in the culture medium for 5 days. The cells were cultured in DMEM/F12 medium (Gibco) supplemented 
with 10% fetal bovine serum (Gibco) and 10% penicillin/streptomycin (Gibco). To analyze the reactive 
oxygen species (ROS) the CellROX® kit (Thermo) was used. Briefly, 500,000 cells were analyzed, samples 
with MFM-300(Sc) and FA@MFM-300(Sc) were incubated during 20 minutes before incubation with H2O2, 
then incubation with hydrogen peroxide (100 mM) was also performed for 20 minutes. After incubation, 
staining was performed with CellRox (500 nM) and 7-AAD (10 μM, BD) for one hour following the 
supplier's instructions. The samples were studied in the FACS Aria III flow cytometer (BD). They were 
analyzed 10,000 events per experimental condition and the percentages of positive cells were obtained 
with the FACS Diva software (BD).  
 
3. Molecular modelling of FER@ MFM-300(Sc) 
 
Details of Monte Carlo and DFT Simulations  
The MFM-300(Sc) crystal structure was taken from a previous experimental work (Ibarra et al., 2011) and 
its atomic positions were relaxed at the Density Functional Theory (DFT) level while keeping the unit cell 
parameters fixed. These calculations were carried out using the CP2K package (Hutter et al., 2014; 
Vandevondele et al., 2005) with a plane wave energy cutoff of 500 Ry and convergence criteria on the 
self-consistent field interactions, maximum atomic displacement and sum atomic forces of respectively 
1×10-6 Ry, 5×10-3 Bohr and 1×10-3 Bohr/Hartree. The atomic orbitals were treated as valence states 
(Goedecker and Teter, 1996; Hartwigsen et al., 1998) and their electronic exchange-correlation 
interactions were treated using a GGA-PBE functional (Perdew et al., 1996, 1997) combined with a 
double-ζ valence plus polarization (DZVP) basis set (Krack, 2005). Long-range dispersion corrections were 
considered using the DFT-D3 correction (Grimme et al., 2010). The atomic partial charges of all atoms of 
the MOF framework  were calculated from this DFT optimised structure using the REPEAT scheme 
(Campañá et al., 2009), as implemented in the CP2K package. The atom types and their respective 
charges are shown in Figure S13. 
The ferulate (FER–) anion was also geometrically optimized using Na+ as compensating cation. This 
optimization was carried out at the DFT level employing a GGA-PBE functional (Perdew et al., 1996, 
1997) combined with a double numerical basis containing polarization functions (DNP), as 
implemented in the Dmol3 module.(Delley, 2000). These calculations were carried out with 
convergence criteria on the self-consistent field interactions, maximum atomic displacement and 
sum atomic forces of respectively 1×10-5 Ha, 5×10-3 Å and 2×10-3 Ha/Å. The Na(FER) atomic charges 
(cf. Figure S14) were calculated using the ESP fitting approach.(Heinz and Suter, 2004)  
In this study, we considered two scenarios: (i) low coverage adsorption of NaFER in anhydrous 
conditions and (ii) high coverage adsorption of NaFER in hydrated conditions. The first scenario had 
as main goal the evaluation of the main NaFER/MFM-300(Sc) interactions while the second one 
allowed us to access the role of the water molecules in the accommodation of the drug in the MFM-
300(Sc) porosity.   
Monte Carlo (MC) simulations in the microcanonical (NVT) ensemble were carried out at 310 K 
considering one FER– anion and one Na+ cation per unit cell. 
Grand Canonical Monte Carlo (GCMC) calculations were first implemented at 1 bar and 310 K. to 
assess the amount of FER–, Na+ and H2O adsorbed in MFM-300(Sc), These MC calculations were 
performed considering 4 unit cells (2×2×1). For each state point, 1×106 Monte Carlo cycles following 
5×103 equilibration cycles (number of steps = number of cycles × number of molecules) were used 
as implemented in the RASPA software.(Heinz and Suter, 2004) As a second step, Monte Carlo (MC) 
simulations in the microcanonical (NVT) ensemble were carried out at 310 K considering the number 
of FER– and Na+ predicted in the first stage but now in the dry MFM-300(Sc) to characterize the 
interactions between the drug molecules and the host framework. 
 
The interactions between the framework and the guest molecules were described considering a sum 
of van der Waals and electrostatic contributions modelled respectively by 12-6 Lennard-Jones (LJ) 
and Coulombic potentials. In the MFM-300(Sc), the LJ parameters were taken from the Dreiding 
(Heinz and Suter, 2004) and Universal(Buchholz et al., 2009) forcefields and respectively assigned to 
the atoms of the organic and inorganic nodes of the framework. The FER– anions were considered 
as flexible with its bonded and LJ parameters obtained from the CGenFF forcefield (Allouche, 2012). 
The Na+ LJ parameters were obtained from a previous simulation work on zeolites (Watanabe et al., 
1995). Finally, water was described by the 4-site TIP4P/2005 model.(Abascal and Vega, 2005) LJ 
crossed parameters were calculated using the Lorentz-Berthelot rules.(Lorentz, 1881) The resulting 
van der Waals interactions were handled with a 12 Å cutoff while the electrostatic interactions were 
obtained using the Ewald summation method with a 10-6 precision.(Ewald, 1921; Vlugt et al., 2008) 
Radial distribution functions (RDFs) averaged over all MC configurations and representative 
snapshots were used to evaluate the preferential interactions and adsorption sites of the guest 
species in the MFM-300(Sc) framework.  
As a complementary, the binding energies between FER– and MFM-300(Sc) in both dry and hydrated 
states were further calculated from DFT-optimised MC configurations. The binding energies (UBE) 
were obtained by the following equation 𝑈!" =	𝑈#$! − (𝑈# + 𝑈!), where UA+B is the energy of the 
adduct NaFER/MOF and NaFER/MOF/Water while UA and UB are the energies of each non-
interacting component, i.e. MOF and NaFER, and MOF-H2O and NaFER respectively. 
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